OpenEvidence Acquires Amaro to Monetize Clinician Traffic

This acquisition shows that OpenEvidence is not treating advertising as a side business, it is building the machinery that lets ads fund a free product for doctors at scale. OpenEvidence already monetizes clinician search traffic with high priced pharma and med device ads, and Amaro adds software for automating ad deployment and optimization, which matters when only a small share of inventory is sold and each impression is unusually valuable.1 2 3 4

• OpenEvidence had already built a large attention business before buying Amaro, with estimates of $150M annualized revenue by November 2025 and $300M by July 2026, driven by physician usage and premium ad pricing rather than hospital subscriptions. That makes better ad tooling directly tied to revenue growth.1 2 3
• Amaro was built around ad automation, helping companies analyze and improve advertising deployment. In practice, that means deciding which sponsor message to show, to which clinician, in which workflow, and learning from performance faster. That is much closer to ad tech plumbing than brand marketing.4 5 6
• The closest public comparison is Doximity, which also turns physician attention into advertising dollars. The difference is that Doximity started with the physician network and added tools, while OpenEvidence started with clinical search and is now adding the monetization stack and adjacent workflow products around it.1 2 7

The next step is a more tightly integrated doctor workflow where search, note taking, calling, prescribing, and sponsored industry messages all sit in one daily habit. If OpenEvidence keeps increasing clinician usage while improving ad yield with Amaro's infrastructure, the free model becomes harder for subscription incumbents to match.1 2 3 4 7